Article
Oncology
Yoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik-Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen-Shi Chen, Li-Yuan Bai, Sung-Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku
Summary: This study investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy for HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer, showing a significant improvement in progression-free survival but not overall survival in Asian patients. The combination therapy may potentially serve as a new first-line treatment option for these patients.
Article
Oncology
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Eva Martinez de Castro, Ana Custodio, Carles Pericay Pijaume, Raquel Hernandez, Gema Aguado, Natalia Castro Unanua, Juana Maria Cano, Flora Lopez, Marcelo Garrido, Ana Fernandez Montes, Laura Visa, Manuel Sanchez Canovas, Maria Luisa Limon, Nieves Martinez Lago, Paola Pimentel, Alicia Hurtado, Aitor Azkarate, Federico Longo, Marc Diez, Aranzazu Arias-Martinez, Tamara Sauri, Alfonso Martin Carnicero, Monserrat Mangas, Marta Martin Richard, Monica Granja, Avinash Ramchandani, Carolina Hernandez Perez, Paula Cerda, Aitziber Gil-Negrete, Mariona Calvo, Rosario Vidal Tocino, Javier Gallego
Summary: The study developed an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer. Results showed that DPF was associated with increased progression-free survival and overall survival compared to PF, but with higher rates of serious adverse events, particularly hematological effects.
Review
Microbiology
Kishen Rajendra, Prateek Sharma
Summary: Tumour virology studies viral pathogens that cause cancer, with approximately 20% of human cancers having a viral etiology. Different viruses play roles at different stages of carcinogenesis and may require co-factors. Oesophageal and gastric malignancies are associated with multiple risk factors, including human papillomavirus (HPV), Epstein-Barr virus (EBV), and Helicobacter pylori (HP). Viral antigen expression in tumors offers potential for prevention and therapy, as demonstrated by successful vaccines for HPV and HBV.
Article
Chemistry, Physical
Lucas Noboru Fatori Trevizan, Josimar O. Eloy, Marcela Tavares Luiz, Raquel Petrilli, Sergio Luiz Ramos Junior, Julio Cesar Borges, Juliana Maldonado Marchetti, Marlus Chorilli
Summary: Liquid crystalline nanodispersions loaded with cetuximab have excellent bioavailability and cytotoxicity, showing better therapeutic effects on prostate cancer cells.
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
(2021)
Article
Oncology
Ricardo Hitt, Ricard Mesia, Alicia Lozano, Lara Iglesias Docampo, Juan J. Grau, Miren Taberna, Jordi Rubio-Casadevall, Javier Martinez-Trufero, Edel del Barco Morillo, Carlos Garcia Giron, Sergio Vazquez Estevez, Beatriz Cirauqui, Juan Jesus Cruz-Hernandez
Summary: This study aimed to demonstrate the non-inferiority of concomitant cetuximab plus radiotherapy (cet+RT) vs cisplatin plus radiotherapy (cis+RT) in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) who were responsive to induction chemotherapy (ICT). The results showed no significant difference in overall survival, progression-free survival, overall response rates, or adverse event rates between the two treatment groups. However, late neurotoxicity was more severe with cis+RT than cet+RT, and improvements in quality of life were observed with cet+RT compared to cis+RT.
Article
Oncology
Samuel L. Cytryn, Ryan H. Moy, Darren Cowzer, Ronak H. Shah, Joanne F. Chou, Smita S. Joshi, Geoffrey Y. Ku, Steven B. Maron, Avni Desai, Jessica Yang, Ryan Sugarman, Devika Rao, Zoe Goldberg, Carmelina Charalambous, Maria Lapshina, Ariel Antoine, Fiona Socolow, Nikhil Trivedi, Marinela Capanu, Hans Gerdes, Mark A. Schattner, Marc Simmons, Mario E. Lacouture, Viktoriya Paroder, Laura H. Tang, Jinru Shia, David H. Ilson, David B. Solit, Michael F. Berger, Yelena Y. Janjigian
Summary: This study evaluated the safety and activity of the combination of regorafenib with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma. The results showed a high survival rate and manageable adverse events.
Article
Oncology
Xue Meng, Anping Zheng, Jun Wang, Xiaoyuan Wu, Guang Li, Jun Zhu, Hu Ma, Xiaodong Zhu, Anhui Shi, Chunhua Dai, Senxiang Yan, Buhai Wang, Zhongyu Qu, Chun Han, Xindong Sun, Ming Ye, Ruitai Fan, Niyazi Huerxidan, Xiaohong Wang, Jinming Yu
Summary: This prospective randomized controlled trial evaluated the efficacy and safety profile of nimotuzumab combined with concurrent chemo-radiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma. Results showed that nimotuzumab group had significantly higher complete response rate and overall response rate compared to the placebo group, with similar rates of adverse drug reactions between the two groups.
BRITISH JOURNAL OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Thais da Silva Moreira, Alan Denis Olivindo Silva, Bianca Rodrigues Farias Vasconcelos, Elias da Silva Santos, Ana Carolina Cruz de Sousa, Joao Vito Barroso de Freitas, Yara Santiago de Oliveira, Laura Maria Teodorio Vidal, Fabio de Oliveira Silva Ribeiro, Alyne Rodrigues de Araujo, Jose de Brito Vieira Neto, Claudia do O. Pessoa, Raquel Petrilli, Josimar O. Eloy
Summary: The study aimed to develop pH-sensitive immunoliposomes based on DOPE and CHEMS for selective drug delivery to EGFR-overexpressing cells in the acidic tumor environment. The liposomes showed appropriate characteristics and successful conjugation with anti-EGFR antibody. The results demonstrated high cytotoxicity and cellular internalization in prostate cancer cells.
Article
Gastroenterology & Hepatology
Elizabeth C. Smyth, Georgios Vlachogiannis, Somaieh Hedayat, Alice Harbery, Sanna Hulkki-Wilson, Massimiliano Salati, Kyriakos Kouvelakis, Javier Fernandez-Mateos, George D. Cresswell, Elisa Fontana, Therese Seidlitz, Clare Peckitt, Jens C. Hahne, Andrea Lampis, Ruwaida Begum, David Watkins, Sheela Rao, Naureen Starling, Tom Waddell, Alicia Okines, Tom Crosby, Was Mansoor, Jonathan Wadsley, Gary Middleton, Matteo Fassan, Andrew Wotherspoon, Chiara Braconi, Ian Chau, Igor Vivanco, Andrea Sottoriva, Daniel E. Stange, David Cunningham, Nicola Valeri
Summary: The study found that EGFR amplification in tissue and plasma cfDNA was correlated with poor survival in patients with advanced gastro-oesophageal adenocarcinoma. Combining EGFR inhibitors with chemotherapy did not improve survival rates, even in patients with significant EGFR CN gains, suggesting important implications for the design of future combinatorial trials.
Article
Surgery
Deguo Yu, Zhenfeng Wang, Tingbang He, Lijun Yang
Summary: This study aimed to evaluate the efficacy and safety of neoadjuvant BEV plus chemotherapy in patients with locally advanced gastric cancer (LAGC). The results showed that this treatment regimen had a favorable pathological response and survival profile, with manageable adverse events.
FRONTIERS IN SURGERY
(2022)
Article
Medicine, General & Internal
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yanez, Mustapha Tehfe, Ruben Kowalyszyn, Michalis V. Karamouzis, Ricardo Bruges, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M. Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A. Ajani
Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.
Review
Oncology
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, Yelena Y. Janjigian, Kohei Shitara
Summary: Despite the lack of clinically relevant biomarkers in the treatment of patients with gastric and gastro-oesophageal junction cancers, advances in identifying molecular subtypes and developing novel therapies are moving towards personalized medicine for individual patients.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Oncology
Birendra Kumar Sah, Wei Xu, Benyan Zhang, Huan Zhang, Fei Yuan, Jian Li, Wentao Liu, Chao Yan, Chen Li, Min Yan, Zhenggang Zhu
Summary: The study demonstrates that the neoadjuvant FLOT regimen is safe and effective for Chinese patients, with the necessity for dose adjustment in adjuvant chemotherapy. Pathological regression and survival rates require reevaluation in a larger cohort.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Tae Jun Kim, Jeung Hui Pyo, Young Hye Byun, Sung Chul Choi, Jin Pyo Hong, Yang Won Min, Hyuk Lee, Byung-Hoon Min, Poong-Lyul Rhee, Jae J. Kim, Jun Haeng Lee
Summary: In high-prevalence areas of gastric cancer, EGD is an effective method for early detection. However, there is still a concern about interval AGC after negative EGD. This study investigated the characteristics and predictors of interval AGC.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Engineering, Biomedical
Chenghua Liang, Xiangyang Bai, Cuiling Qi, Qingxue Sun, Xiaoyan Han, Tianyun Lan, Haibo Zhang, Xiaoming Zheng, Rongpu Liang, Ju Jiao, Zongheng Zheng, Jiafeng Fang, Purun Lei, Yan Wang, Diana Moeckel, Josbert M. Metselaar, Gert Storm, Wim E. Hennink, Fabian Kiessling, Hongbo Wei, Twan Lammers, Yang Shi, Bo Wei
Summary: Electron-stabilized polymeric micelles loaded with docetaxel showed high efficiency in enhancing chemotherapy responses in advanced-stage GI cancer mouse models, achieving complete cures and tumor regression in both CDX and PDX models. Moreover, the micellar docetaxel modulated the tumor immune microenvironment and was well-tolerated toxicologically, indicating significant potential for the treatment of advanced-stage GI cancers.
Article
Oncology
Rachel Woodford, Daniel Brungs, Carly Leighton, Peter Grimison, Katrin M. Sjoquist, Therese Becker, Samuel Robinson, Val Gebski, Kate Wilson, Lorraine Chantrill, Morteza Aghmesheh
Summary: This study demonstrates the feasibility and potential efficacy of combination therapy with capecitabine and nab-paclitaxel as a second-line treatment for ABTC, warranting further assessment in formal phase II or III trials. The treatment was generally well tolerated, with encouraging disease control rates and survival outcomes.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Paul A. Cohen, Penelope M. Webb, Madeleine King, Andreas Obermair, Val Gebski, Phyllis Butow, Rachael Morton, Wanda Lawson, Patsy Yates, Rachel Campbell, Tarek Meniawy, Michelle McMullen, Andrew Dean, Jeffrey Goh, Orla McNally, Linda Mileshkin, Philip Beale, Rhonda Beach, Jane Hill, Cyril Dixon, Sue Hegarty, Jim Codde, Angela Ives, Yeh Chen Lee, Alison Brand, Anne Mellon, Sanela Bilic, Isobel Black, Stephanie Jeffares, Michael Friedlander
Summary: The study aims to evaluate the emotional wellbeing, acceptability, safety, and cost effectiveness of nurse-led telehealth follow-up for women with ovarian cancer. It is hypothesized that this telehealth follow-up model will improve emotional wellbeing, increase patient satisfaction, identify patients with psychological distress, and be cost-effective. The results are expected to be published in 2025, 24 months after the last participant is enrolled.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Pediatrics
Ju Lee Oei, Vishal Kapadia, Yacov Rabi, Ola Didrik Saugstad, Denise Rook, Marijn J. Vermeulen, Nuria Boronat, Valerie Thamrin, William Tarnow-Mordi, John Smyth, Ian M. Wright, Kei Lui, Johannes B. van Goudoever, Val Gebski, Maximo Vento
Summary: In this study, resuscitation with lower or higher initial FiO2 was not associated with the risk of death or disability at 2 years in infants under 32 weeks gestation. However, the wide confidence intervals indicate that conclusive evidence is lacking, and larger randomized studies are urgently needed to further investigate the potential benefits or harms of different initial FiO2 levels on infant outcomes.
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION
(2022)
Article
Multidisciplinary Sciences
Fiona Chionh, Val Gebski, Sheren J. Al-Obaidi, Jennifer K. Mooi, Maressa A. Bruhn, Chee K. Lee, Anderly C. Chueh, David S. Williams, Andrew J. Weickhardt, Kate Wilson, Andrew M. Scott, John Simes, Jennifer E. Hardingham, Timothy J. Price, John M. Mariadason, Niall C. Tebbutt
Summary: The study found that SNPs in the VEGF-A and VEGFR2 genes may have predictive value for treatment outcomes and the development of hypertension in patients with colorectal cancer.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Peey Sei Kok, Patrick M. Forde, Brett Hughes, Zhuoxin Sun, Chris Brown, Suresh Ramalingam, Alistair Cook, Willem Joost Lesterhuis, Sonia Yip, Ken O'Byrne, Nick Pavlakis, Julie Brahmer, Valsamo Anagnostou, Kate Ford, Karen Fitzpatrick, Alison Bricker, Michelle M. Cummins, Martin Stockler, Anna K. Nowak
Summary: The DREAM3R trial aims to assess the efficacy of combining PD-L1 inhibitor durvalumab with first-line chemotherapy in pleural mesothelioma. This multicentre, open-label randomized trial will recruit 480 treatment-naive patients and evaluate various endpoints, including overall survival and adverse events.
Article
Oncology
K. E. Francis, S. Kim, M. Friedlander, V Gebski, I Ray-Coquard, A. Clamp, R. T. Penson, A. Oza, T. Perri, T. Huzarski, C. Martin-Lorente, S. C. Cecere, N. Colombo, B. Ataseven, K. Fujiwara, G. Sonke, I Vergote, E. Pujade-Lauraine, J-W Kim, C. K. Lee
Summary: Using data from the SOLO2 trial, this study evaluated the impact of dose alterations on survival outcomes of olaparib treatment and identified baseline characteristics associated with dose alteration.
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
N. Murray, P. Francis, N. Zdenkowski, N. Wilcken, F. Boyle, V. Gebski, S. M. Tiley, L. Gilham, S-J. Dawson, S. Loi, A. D. Redfern, J. Lombard, A. Spillane, C. Shadbolt, H. Badger
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Sina Vatandoust, David Wattchow, Luigi Sposato, Michael Z. Michael, John Leung, Kirsten Gormly, Gang Chen, Erin L. Symonds, Jeanne Tie, Lito Electra Papanicolas, Susan Woods, Val Gebski, Kelly Mead, Aleksandra Kuruni, Christos S. Karapetis
Summary: This study aims to investigate the safety of the watch and wait approach for rectal cancer patients, as well as explore the use of predictive biomarkers and patient reported outcome measures. It also seeks to evaluate a defined monitoring schedule for patients managed with the watch and wait approach, and assess the cost effectiveness of this approach.
Article
Oncology
R. Mercieca-Bebber, E. H. Barnes, K. Wilson, Z. Samoon, E. Walpole, T. Mai, S. Ackland, M. Burge, G. Dickie, D. Watson, J. Leung, T. Wang, R. Bohmer, D. Cameron, J. Simes, V Gebski, M. Smithers, J. Thomas, J. Zalcberg, A. P. Barbour
Summary: This study evaluates the patient-reported outcomes (PROs) of different treatment groups in patients with resectable oesophageal adenocarcinoma. The results show that similar proportions of patients in different treatment groups had PRO scores within 10 points of their baseline scores, indicating similar symptom experiences. However, non-responders who received docetaxel with or without radiotherapy experienced additional burden compared to responders, reflecting the longer duration of neoadjuvant treatment and additional toxicity.
Review
Oncology
Katrin M. Sjoquist, Andrew Martin, Nick Pavlakis, David Goldstein, Eric Tsobanis, Daniel Moses, Richard Maher, Wendy Hague, Val Gebski, Martin R. Stockler, R. John Simes
Summary: This study assessed the value of central review in evaluating PFS times in phase 2 clinical trials and found that it supported the reliability of trial results and conclusions.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Deborah Smith, Kristy P. Robledo, Sonia Yip, Michelle M. Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda Mileshkin, Yoland Antill
Summary: Until recently, the outcome for women with advanced endometrial carcinoma has been poor. New immune therapies have improved outcomes for some women, but determining which women will respond is important. This study aimed to find markers to better predict response to immunotherapy. Tumor-associated inflammatory cells were found to have the strongest association with response. A novel algorithm using optimal cutoff points was able to identify non-responders with high sensitivity. Further validation is needed.
Article
Oncology
Neville F. Hacker, Ellen L. Barlow, Glenn McNally, Stephen Morrell, Val Gebski, Andreas Obermair
Summary: Vulvar cancer is a rare disease that often leads to body image issues due to its treatment. Chronic lower limb lymphedema is a common problem after the removal of groin lymph nodes. The status of these nodes is crucial for prognosis, and most patients require groin dissection. A pilot study on 32 patients showed promising results for serial ultrasonography as a potential alternative to groin dissection in selected patients. The study achieved a high sensitivity and specificity in detecting positive nodes, supporting the need for further research on this approach.
Article
Genetics & Heredity
Daniel R. A. Cox, Tess McClure, Fan Zhang, Boris Ka Leong Wong, Adam Testro, Su Kah Goh, Vijayaragavan Muralidharan, Alexander Dobrovic
Summary: Both graft-specific DNA methylation analysis and donor-recipient genotyping techniques successfully quantified gdcfDNA in patients post-liver transplantation, with significant correlation. While the two techniques performed similarly, gdcfDNA monitoring based on graft-specific DNA methylation patterns in cfDNA offers greater practical advantages and enhances the potential for clinical translation.
Article
Medicine, General & Internal
Meg J. Jardine, Sradha S. Kotwal, Abhinav Bassi, Carinna Hockham, Mark Jones, Arlen Wilcox, Carol Pollock, Louise M. Burrell, James McGree, Vinay Rathore, Christine R. Jenkins, Lalit Gupta, Angus Ritchie, Ashpak Bangi, Sanjay D'Cruz, Andrew J. McLachlan, Simon Finfer, Michelle M. Cummins, Thomas Snelling, Vivekanand Jha
Summary: The study aimed to determine whether using angiotensin receptor blockers could improve clinical outcomes in people with covid-19. The results showed no evidence of benefit when using telmisartan, predominantly at a dose of 40 mg/day, as an angiotensin receptor blocker in hospitalized patients with mild covid-19.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Meeting Abstract
Oncology
Bruce Mann, Allison Rose, Janemary Hughes, Anita R. Skandarajah, Anand Murugasu, Andrew John Spillane, Boon Hui Chua, Nicholas Zdenkowski, Helen Braggett, Heath Badger, Renee Eggins, Val Gebski, Allan Park, Kaley Schwartz, Arlene Mou, John Collins
JOURNAL OF CLINICAL ONCOLOGY
(2022)
